ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 024

Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging

Mark DiFrancesco, Ekemini Ogbu, Catherine Robben, Jennifer Huggins and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Cerebrovascular disease, CNS Lupus, corticosteroids, Magnetic resonance imaging (MRI), Neuroimaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Poster Breakout 3 - Pediatric Rheumatology Potpourri

Session Type: Breakout Session

Session Time: 5:10PM-5:40PM

Background/Purpose: Prior research suggests that microvascular (MV) changes might be a biomarker for central nervous system (CNS) involvement of patients with systemic lupus erythematosus (SLE). Given that corticosteroids (CS) are widely used for the treatment of SLE and could also influence MV changes, CS effects need to be distinguished from MV changes secondary to CNS disease. We aimed to quantify and isolate the dose-dependent effects of oral CS on MV properties as assessed by diffusion-weighted imaging (DWI).

Methods: Using convenience sampling, 11 patients with chronic inflammatory conditions were enrolled and studied at two visits: (1) the time of high dose CS use (HD-CS; prednisone >20 mg/day) and (2) after tapering to low dose (LD-CS). At each study visit, cognitive ability was measured using the Pediatric Neuropsychological Assessment Metrics (PedANAM) and MRI was acquired at 3-Tesla, including T1 and T2 relaxometry, blood-brain-barrier permeability measurement by arterial spin labeling, and diffusion weighted imaging (DWI) at 19 weightings (b-values) ranging from 0 to 5000 s/mm2. DWI signal was analyzed as a biexponential function of b-value under the intravoxel incoherent motion (IVIM) model. Besides bulk tissue diffusion (D), the IVIM model provides parameters describing microvasculature including pseudodiffusion (D*), dependent on flow through randomly-oriented microvessels, the volume fraction of blood (vbw), and their product, D* x vbw, proportional to blood perfusion. Voxel-wise change in each IVIM parameter was calculated between the HD-CS and LD-CS visits for each patient. Parameter changes were fitted across patients to a linear model including 2 terms 1) the mean parameter change and 2) the degree of CS dose reduction between HD-CS and LD-CS. Model results were expressed as effect size, represented by Cohens f2, for the coefficients of the mean and dose reduction terms. with Cohens f2 > 0.35 considered a large effect size.

Results: All patients completed the HD-CS visit and 9 the LD-CS visit. Table 1 summarizes patient characteristics. Regionally, there were mean changes in the 4 IVIM parameters between HD-CS and LD-CS with f2 > 0.35, . (Figure 1). Similarly, the dependence of parameter changes between HD-CS and LD-CS on the amount of dose reduction also had large effect size regionally (f2 > 0.35) (Figure 2). Vascular parameters were mostly greater at HD-CS, with increases in the blood perfusion-related product, D* x vbw, especially widespread. There was mostly positive dependence of vascular parameters with degree of dose reduction.

Conclusion: This pilot study provides evidence of at least moderate impact of oral CS on CNS MV as measured by DWI results in SLE. Further, CS impact on brain MV varies regionally across the brain. If confirmed in a larger cohort, the parameter estimates from this study can be used to isolate the brain MV effects from the inflammation associated with CNS lupus from those caused by CS treatment.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. DiFrancesco: None; E. Ogbu: None; C. Robben: None; J. Huggins: None; H. Brunner: GENENTECH, 12, provision of study drug for NIAMS funded study, Pfizer, 1, 2, 6.

To cite this abstract in AMA style:

DiFrancesco M, Ogbu E, Robben C, Huggins J, Brunner H. Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/effects-of-corticosteroids-on-central-nervous-system-microvascular-properties-assessed-by-neuroimaging/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-corticosteroids-on-central-nervous-system-microvascular-properties-assessed-by-neuroimaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology